metipranolol ophthalmic (Discontinued)

Brand and Other Names:OptiPranolol (DSC)
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

ophthalmic solution

  • 0.3%

Open-Angle Glaucoma

1 gtt in affected eye(s) q12hr

Safety & efficacy not established

Next:

Interactions

Interaction Checker

and metipranolol ophthalmic

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            Frequency Not Defined

            Ocular

            • Burning sensation in eye
            • Blepharitis
            • Blurred vision
            • Light intolerance
            • Uveitis
            • Tearing
            • Eyelid dermatitis
            • Browache

            Systemic

            • Similar to systemic beta-blockers including bradycardia, aggravation of CHF, nausea, asthma, nightmares, impotence, tiredness, cough, dyspnea, epistaxis, rhinitis, myalgia, arthritis, rash
            • Reduction of systemic side effects by putting finger in corner of eye (occluding punctum) or by gentle eyelid closure (without opening & closing lid) for 3 min
            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity

            Asthma, uncompensated CHF, severe COPD, symptomatic sinus bradycardia, 2nd or 3rd degree AV block, cardiogenic shock

            Cautions

            Caution in diabetes (may mask signs of hypoglycemia)

            Caution on inadequate cardiac function, latent cardiac insufficiency, cerebrovascular insufficiency, sick sinus syndrome, peripheral vascular disease, history of psychiatric illness, heart failure, diminished pulmonary function, nonallergic bronchospasm, diabetes mellitus, myasthenia gravis

            Patients receiving topical levobunolol & a systemic ß-adrenergic blocking agent concomitantly should be observed carefully for potential additive effects on IOP &/or systemic effects of ß-adrenergic blockade

            May mask signs of hyperthyroidism (ie, tachycardia)

            Remove contact lens prior to administration

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: Excretion in breast milk unknown; use caution

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Nonselective beta-adrenergic receptor blocker; lacks intrinsic sympathomimetic activity and membrane stabilizing effects; reduces IOP by reducing production of aqueous humor

            Pharmacokinetics

            Onset of action: <30 min

            Peak effect: ~2 hr

            Half-life: 3 hr

            Duration: Up to 24 hr (intraocular pressure reduction)

            Previous
            Next:

            Images

            Previous
            Next:
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.